Transcatheter edge-to-edge repair (TEER): Past, current and future perspectives
10.7507/1007-4848.202104067
- VernacularTitle:经导管二尖瓣缘对缘修复（TEER）的过去、现在和未来
- Author:
Wenzhi PAN
1
,
2
;
Yuliang LONG
1
,
2
;
Daxin ZHOU
1
,
2
;
Junbo GE
1
,
2
Author Information
1. 1. Department of Cardiology, Zhongshan Hospital, Fudan University, Research Unit of Cardiovascular Techniques and Devices, Chinese Academy of Medical Sciences, Shanghai, 200032, P.R.China
2. 2. National Clinical Research Center for Interventional Medicine, Shanghai, 200032, P.R.China
- Publication Type:Journal Article
- Keywords:
Transcatheter edge-to-edge repair (TEER);
mitral regurgitation;
progress
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2021;28(12):1409-1414
- CountryChina
- Language:Chinese
-
Abstract:
Transcatheter edge-to-edge repair (TEER) originated from surgical edge-to-edge repair. MitraClip is the first mature TEER device, and the TEER based on MitraClip is far ahead of many transcatheter mitral valve repair (TMVr) technologies in terms of safety, effectiveness and popularity, so it is named separately in the latest guidelines. The TEER has the following advantages: consistent with basic medical principles, few implants, precise target, less invasive and repeatable. However, there are also some shortcomings, such as the relatively complex design of transfemoral device, target single and relatively narrow indications. At present, the main clinical data of TEER are mainly from the clinical practice of MitraClip. Based on the three-year outcomes of COAPT study, both 2020 ACC/AHA guideline and 2020 ACC expert consensus decision pathway on the management of mitral regurgitation recommend in patients with chronic heart failure with left ventricular dysfunction and severe mitral regurgitation in nonresponders to medicine treatment. Edward's PASCAL, another TEER device, has two models. Among the domestic TEER devices, the ValveClamp of Hanyu medical technology has many distinct advantages, such as simple operation, large clamping area, high clamping efficiency and no need of X-ray. DragonFly, another domestic TEER device, has also completed its feasibility study. There are five trends of TEER in the future: further expansion of indications, combination with other interventional techniques, repeatable operations, transcatheter mitral valve replacement after TEER, and continuous improvement and innovation of equipment.
